Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Firazyr, icatibant, Date of authorisation: 11/07/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Baiama, aflibercept, Date of authorisation: 13/01/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 7, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Zulvac 1+8 Ovis, inactivated bluetongue serotype 1+8 vaccine, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Zulvac 1+8 Bovis, inactivated bluetongue virus, serotypes 1 and 8, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Zulvac 8 Ovis, inactivated bluetongue virus, serotype 8, Status: Authorised

Veterinary medicines European public assessment report (EPAR): VarroMed, oxalic acid dihydrate / formic acid, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Veltassa, patiromer sorbitex calcium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0313/2024

Veterinary medicines European public assessment report (EPAR): UpCard, torasemide, Status: Authorised